Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
NUFYMCO BLA has been approved by the USFDA
UK headquartered digital health scale-up strengthens global tech and innovation footprint in the country
Tablets will be manufactured at Granules' US-based facility located in Chantilly, Virginia
The initiative is focused on a problem that continues to plague cancer outcomes in India
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
This recognition demonstrate excellence in intellectual property (IP) value creation.
Subscribe To Our Newsletter & Stay Updated
